A paper published in this weeks Journal of Clinical Oncology says Transforming Growth Factor Beta Receptor 1*6A (TGFBR1*6A) – a mutated gene present in nearly one in eight people and the most commonly inherited cancer susceptibility gene identified so far – might be responsible for a significant proportion of familial colorectal cancers. The study, published by researchers at Northwestern Memorial Hospital and Northwestern Universitys Robert H. Lurie Comprehensive Cancer Center, says 15 to 20 percent of all colorectal cancers are familial, but only 7-8 percent are caused by mutations of known colorectal cancer genes such as the APC, MLH1, MSH2 and MSH6 genes.
In an earlier study, Dr. Pasche and his colleagues had found that TGFBR1*6A may increase the risk for all colon cancers by 20 percent. "There is growing evidence that TGFBR1*6A is associated with an increased risk of colorectal cancer but its specific contribution to familial colorectal cancer was unknown," explained Dr. Pasche. Now, Dr. Pasche believes the gene is especially potent as a cause for familial colon cancers.
The study looked at 208 patients with colorectal cancer and a strong family history of colorectal cancer and found that the number of TGFBR1*6A carriers was twice as high among patients without a mutation in the colorectal cancer genes MLH1, MSH2 and MSH6 as compared with patients without a mutation in these genes. The number of carriers of two copies of the TGFBR1*6A gene was 13-fold higher than in the general population, suggesting that TGFBR1*6A homozygosity (possessing two identical forms of a particular gene, one inherited from each parent) is associated with a particularly high risk of colorectal cancer.
Amanda Widtfeldt | EurekAlert!
Lethal combination: Drug cocktail turns off the juice to cancer cells
12.12.2018 | Universität Basel
Smelling the forest – not the trees
12.12.2018 | Universität Konstanz
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...
What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.
Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
13.12.2018 | Awards Funding
13.12.2018 | Earth Sciences
13.12.2018 | Materials Sciences